Literature DB >> 1616599

The human hepatic cytochromes P450 involved in drug metabolism.

S A Wrighton1, J C Stevens.   

Abstract

The cytochromes P450 are a superfamily of hemoproteins that catalyze the metabolism of a large number of xenobiotics and endobiotics. The type and amount (i.e., the animal's phenotype) of the P450s expressed by the animal, primarily in the liver, thus determine the metabolic response of the animal to a chemical challenge. A majority of the characterized P450s involved in hepatic drug metabolism have been identified in experimental animals. However, recently at least 12 human drug-metabolizing P450s have been characterized at the molecular and/or enzyme level. The characterization of these P450s has made it possible to "phenotype" microsomal samples with respect to their relative levels of the various P450s and their metabolic capabilities. The purpose of this review is to compare and contrast the human P450s involved in drug metabolism with their related forms in the rat and other experimental species.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616599     DOI: 10.3109/10408449209145319

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  139 in total

1.  The potential for drug interactions with statin therapy in Ireland.

Authors:  A Heerey; M Barry; M Ryan; A Kelly
Journal:  Ir J Med Sci       Date:  2000 Jul-Sep       Impact factor: 1.568

Review 2.  Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.

Authors:  K Wilbur; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 3.  Drug trials in children: problems and the way forward.

Authors:  S Conroy; J McIntyre; I Choonara; T Stephenson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 4.  Drug metabolism and ageing.

Authors:  M T Kinirons; M S O'Mahony
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

5.  Prioritization of SNPs for genome-wide association studies using an interaction model of genetic variation, gene expression, and trait variation.

Authors:  Hyojung Paik; Junho Kim; Sunjae Lee; Hyoung-Sam Heo; Cheol-Goo Hur; Doheon Lee
Journal:  Mol Cells       Date:  2012-03-28       Impact factor: 5.034

6.  Anti-epileptic drugs and hormonal treatments.

Authors:  Clare A Johnston; Pamela M Crawford
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

7.  Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.

Authors:  Terri S Armstrong; Yumei Cao; Michael E Scheurer; Elizabeth Vera-Bolaños; Rochelle Manning; Mehmet F Okcu; Melissa Bondy; Renke Zhou; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

8.  Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies.

Authors:  P Bonnabry; J Sievering; T Leemann; P Dayer
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans.

Authors:  Zaiqi Wang; Stephen D Hall; Juan F Maya; Lang Li; Ali Asghar; J C Gorski
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

10.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Authors:  E A Sotaniemi; A Rautio; M Bäckstrom; P Arvela; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.